Rethink: The Story of Edward de Bono in Australia Case Study CHAPTER 7 PFIZER AUSTRALIA: FRESH IDEAS ARE JUST THE MEDICINE
When Paul Epstein joined pharmaceutical company Pfizer Australia in 2004 his
immediate challenge was to develop an innovation program for Pfizer’s consumer
healthcare (PCH) division. As the division’s head of strategy and project development,
Epstein was responsible for steering the PCH Innovation Group – comprising business-
unit heads from across the division – which created and managed the program dubbed
the Innovation Drive. The Innovation Drive was progressively rolled out across Australia
and New Zealand in the second half of 2004 and remains an active program. The
objective of the program was to ensure that innovation – or more specifically, “innovative
thinking” – became an everyday way of working at Pfizer. In fact, this goal was the focus
of a global review of innovation strategies and programs then underway at US-based
pharmaceutical giant Pfizer Inc. Pfizer Australia, however, was free to devise its own
program, a challenge Epstein and his team accepted with gusto.
Epstein was determined to take a systemic approach to innovation – empowering
employees to think creatively by providing them with the tools and techniques to
Rethink: The Story of Edward de Bono in Australia
innovate, creating the framework for their ideas to be heard and considered, and having
the systems in place to harvest the fruits of their creativity. Epstein wanted to introduce
consistency to the innovative process, but not be so bureaucratic that it stifled interest.
His aim was to provide employees with the resources to contribute to the company and
have some control of their personal and professional destiny as Pfizer employees.
For Epstein, a longtime admirer of Edward de Bono, the challenge of instilling a culture
of innovative thinking was the perfect scenario for introducing de Bono’s creative
thinking tools. “Edward de Bono has stood the test of time because of the power and
simplicity of his tools. This was the ideal environment for introducing his tools,” Epstein
explains.1 However, before introducing the de Bono tools, first he had to get the structure
The program was introduced progressively over three stages: Explore, Empower and
Engage. Privately it was dubbed the Crawl, Walk, Run approach. Between each phase,
progress was reviewed and refinements made as necessary. Before introducing
employees to de Bono’s tools, Epstein wanted to be sure that everyone understood
innovation and its importance to Pfizer.
Pfizer can trace its origins to 1849 with the founding of fine-chemical manufacturer
Charles Pfizer & Company in Brooklyn, New York. Today it is the world’s largest
pharmaceutical and healthcare company. With research and development expenditure
of US$7.4 billion in 2005 and 12,500 scientists employed at research facilities around
the world, Pfizer is a company built on innovation. The issue of The Pfizer Journal
marking the company’s 150th anniversary in 1999 was dedicated to the theme, ‘The
Importance of Innovation in Pharmaceutical Research’. In his editorial, editor-in-chief Dr
Salvatore Giorgianni wrote: “Innovation is one of the core principles that has defined
Pfizer in scientific discovery throughout the years … Focusing on innovation has made
this corporation unusually successful.”2
Pfizer is a company with a well honed sense of corporate self and a rich corporate
culture which honours its long and distinguished history of innovation, but which is
equally motivated by discoveries yet to be made. Pfizer’s corporate website proclaims:
“The pursuit of innovation is basic to Pfizer's culture. It shapes our strategy, defines our
Rethink: The Story of Edward de Bono in Australia
purpose, and governs every facet of our operations.” Innovation is enshrined in the
company’s nine corporate values – along with integrity, respect for people, customer
focus, community, teamwork, performance, leadership and quality.
As one would expect of a company founded in the mid-19th century, Pfizer has
experienced remarkable change on the road to becoming a global leviathan in the
discovery, development, manufacture and marketing of prescription medicines and
healthcare products.3 Innovation has been a cornerstone value throughout. Giorgianni’s
anniversary editorial noted: “Over this century and a half, Pfizer has reinvented itself as a
corporation several times … Throughout Pfizer’s 150 years, the common strategies and
elements of our success and growth have been innovation and a focus on the needs of
For Pfizer, the stakes associated with maintaining its innovative edge are high.
Innovation is not only a key to its past, but more critically, to its future as well, as
underlined in Pfizer’s charter of values, “Innovation is the key to improving health and
sustaining Pfizer's growth and profitability.”
It was against such a formidable backdrop that Paul Epstein and the Innovation Group
set out to develop a new innovation program for Pfizer Australia’s consumer healthcare
group. (Internationally, Pfizer has three business segments: prescription medicines,
consumer healthcare and animal health.) Pfizer Consumer Healthcare is responsible for
over-the-counter medicine brands such as Benadryl, Codral, Listerine, Mylanta, Sudafed
and Nicorette. In Australia and New Zealand, PCH employs 200 people in
administration, sales and marketing, R&D, and regulatory affairs.
The Innovation Group’s program had the support and active interest of Pfizer’s then
regional director of PCH, Joseph Saad. This was important, according to Epstein,
“because it gave the project momentum and an acknowledgement that this is where
Pfizer was headed globally”. He continues: “The business globally was looking to weave
innovation into the fabric of the entire organisation, to ensure that innovation, and more
specifically, innovative thinking, became an everyday part of working at Pfizer. And it had
to engage everyone. That was the objective: a true cultural shift.”
Rethink: The Story of Edward de Bono in Australia
Programs aimed at encouraging and rewarding innovation at Pfizer were not new. Pfizer
Australia employees had access to local and international idea exchanges, innovation
intranets and award programs, but such initiatives did not constitute systematic progress
towards a whole-of-company culture of innovation. As often happens with such
programs, their appeal was less than universal. Epstein, who was determined to create
an innovation program that was genuinely inclusive, believes the composition of the
Innovation Group was an important factor in the program’s success. Team members
included colleagues with “some serious years at Pfizer under their belts”, according to
Epstein. “This was critical to the success of the program in that we had a very robust
sounding board with a real feel for what would or wouldn’t work when developing the
An early priority of the group was not to alienate employees by making the innovation
program complicated or process-driven. “The greatest challenge was to demystify the
innovation process by starting out with a simple premise and approach. We were mindful
of not reinventing the wheel. It was also a firm belief that an innovative culture, especially
to begin with, needed to be developed inside out, rather than outside in,” Epstein recalls.
A deliberate decision was made not to include external consultants in the formative
stages of the program, ensuring that the innovation strategies that unfolded were
homegrown and not imposed on employees.
Another early decision that would influence the development of the program was to
position innovative thinking as an attitude – a “mindset”. If employees could be
convinced of the value of innovation from the outset, enough to make a personal
commitment to innovation, then setting directions for the program would follow as a
natural progression. Innovation, therefore, needed to be more than a manifesto, it had to
be a living goal, based on actions. Thus the Innovation Group’s working credo: Action,
The locally developed PCH innovation vision – “Making Things Better” – reflected this
practical approach. This somewhat prosaic catchcry was broken down to its constituent
parts so that employees could understand what things could be made better. More than
a slogan, it was a wish-list: Making Things Better for … consumers, employees,
manufacturing operations, how PCH does business, for stakeholders, and how Pfizer
develops “new thinking and fresh ideas”. Innovation was not about the attainment of lofty
Rethink: The Story of Edward de Bono in Australia
and abstract goals, but of simple, recognisable and achievable outcomes that
employees could identify with. These were values with an everyday resonance.
Achieving them was something every employee could have a stake in, whether working
as a receptionist or a research scientist. An early priority of the Innovation Group was to
reinforce with employees that the goal of building an innovative culture was a goal for
the whole enterprise, not just for the R&D department. Accordingly, new ideas could
relate to products, processes or people.
Epstein was clear in the approach to be taken. The two clearly stated objectives for the
program were creating new product development – “NPD pipe-fill” in industry parlance –
and achieving an “innovative culture shift”. He recalls:
“We started with a pretty headstrong approach: this was going to be about action not just
talk. But we also knew that the program needed to be as open, involving and fun as
possible if it was to become contagious and achieve the desired culture status. This was
not about imposing a new order. We wanted innovation to become an embedded way of
working at Pfizer, but we knew that for innovation to catch on, we needed to build a
sense of ownership from the ground up.”
The innovation program was launched in August 2004. A critical feature of the program
was its progressive nature, to be introduced in three stages: Exploration, Empowerment
Stage 1: Exploration
For most employees, setting time aside for deliberate creative thinking came as naturally
as walking backwards. The aim of the exploration stage was to get employees used to
thinking, and more importantly, to take a structured approach to thinking. A memo to
attend thinking classes was not going to do it. This would require a personal commitment
to innovation from each employee. Epstein admits that the early indicators were not
encouraging. The standard response from sceptical employees was that they didn’t have
the time for new thinking. “I’m sure anywhere in the world that would be the standard
catchcry: we don’t have time for that. So we said, ‘what if we ask you to set aside just
Rethink: The Story of Edward de Bono in Australia
1% of your time to think innovatively, is that too much to ask?’. In most cases the reply
Over two months – August and September – employees were required to spend a
minimum of 30 minutes per week “thinking innovatively” with the objective of “making
things better”. It was important not to over-formalise these early steps into a structured
thinking program; employees were assured that it was up to them when and where they
found their 30 minutes of thinking time. It could literally be anytime – over coffee or when
driving to work – with a colleague or alone. The aim was to get everyone into the habit of
setting aside some thinking time once a week. Employees were urged: “Wherever you
may be when you come up with the thought, scribble it down on the back of an
envelope”. The aim was that each person would come up with one idea per week. These
ideas would be fed by employees into a dedicated intranet site as part of the established
NPD project management program called SCIP: Strategic Co-ordination of Innovative
A focus of this first phase was encouraging people to share their thinking and ideas.
“Initially we wanted to get them to expel ideas they’d been sitting on for a number of
years. Once they got these out of their system they could start to come up with new and
During this time employees, while encouraged to come up with new ideas by “thinking
innovatively”, were not provided with any tools to assist the process. Employees had,
however, been informed that training in ‘thinking tools’ would take place later in the
program. This was a critical and deliberate strategy as Epstein explains: “After several
weeks people were getting pretty dry [of ideas]. It made them realise how difficult it is to
come up with new ideas on a regular basis. Sustaining creativity requires tools and after
a few weeks they were hungry for these tools.”
Stage 2: Empowerment
The empowerment phase ran over October and November 2004. During this time,
employees were still required to set aside 30 minutes’ thinking time a week and to come
up with one idea each week. It was at this point that Epstein brought in the consultants,
Rethink: The Story of Edward de Bono in Australia
or more accurately, the trainers, from the Melbourne-based de Bono Institute.
Employees attended a full-day workshop on de Bono’s thinking tools and techniques,
conducted by accredited trainers Susan Mackie and Kendra Overall. The workshop, held
in October, was attended by 130 out of PCH’s 200 employees. (The remaining
employees – the division’s sales force – did their de Bono training in February the
following year.) Employees were introduced to parallel thinking (Six Thinking Hats) and
two Lateral Thinking tools, Random Word and Concept Triangle.
Epstein says the timing of the training was critical. Introducing the de Bono tools weeks
into the innovation program ensured that the focus remained on innovation as the
cultural imperative. The tools – being just that – would assist in achieving that goal,
indeed would prove integral to achieving that goal, but the tools were not the ultimate
“This progressive approach was about building the habit of creative thinking. Stage one
was about getting the basics down, understanding innovation and its application to
Pfizer, and reinforcing the point that everyone can participate in an innovative culture. A
lot of people genuinely believe that creativity is a special talent that only some people
have, or they believe that in their particular job they’re not expected to be creative. Stage
one was about giving people a taste of what it’s like to develop new ideas from a blank
sheet of paper, stage two was about equipping people with the tools to think creatively.”
Employees were free to choose the tools and techniques that worked best for them but
were now required to direct their thinking to a focus topic.
During this time employees logged their ideas online to a simple formula that gave a
bare description of each idea. Ideas were systematically collated, filtered and assessed
by team leaders. Once a month, 40 team leaders met with their teams for one hour.
Originators of ideas read out their idea for quick feedback from the team. These “Hatch-
it” sessions provided the first round of filtering. Ideas were deemed either “contenders” –
thus progressing from “idea” to “opportunity” for further consideration – or “backburners”,
shelved but not forgotten. Originators of ideas still in contention were then required to
elaborate on their ideas into a one-page summary, for consideration by the Genesis
Group, which met monthly to review opportunities and anoint ideas. The Genesis Group,
Rethink: The Story of Edward de Bono in Australia
described by Epstein as a “cross-matrix management team”, would determine whether
the ideas had early potential or needed to be further developed before being presented
to the New Product Portfolio (NPP) senior leadership team. Ideas for new products or
processes, once approved by the leadership team, would be assigned to a project team
as active projects for development. From the original lodgement of an idea to status as
If the innovation program was going to die, it was going to be at this point. Employees
would either feel the process was a waste of time, or they would embrace it, or at least
give it the benefit of the doubt, as a real opportunity to contribute. “The program was well
received. It wasn’t resented by anyone. They knew this was about the future of their
company as much as it was about their own futures. This was about personal
development and future business development,” Epstein says.
Between August and November, 1,200 ideas were logged. Of those, 60% were product-
focused, 25% were about process and 15% were about people issues. Epstein says the
spread of ideas was as important as the number of ideas received: a focus on one
particular area would have suggested entrenched cultural problems. “If we had 80% of
ideas around people or process, we’d know that potentially we had some significant
The most telling indicator of the program’s success was reflected in employee surveys
conducted in June 2004, prior to the launch of the program, and immediately following
the conclusion of Stage 2 in late November 2004. The survey, based on agreement
(‘agree strongly’) with given statements, revealed a clear shift in employee attitudes on
• “I know what is expected of me when it comes to innovation at PCH”: 38%
agreed strongly in June 2004 / 58% agreed strongly in November 2004.
• “It’s simple and easy to submit new ideas”: 45% / 74%
• “There is an effective innovation program in place”: 37% / 72%
• “We’ve been given the tools/techniques to help us think innovatively”: 35% / 69%
Rethink: The Story of Edward de Bono in Australia
“By this stage we knew the program had traction. There was no turning back now,”
Epstein recalls with undiminished satisfaction. Stage 3: Engagement
In February 2005, the Innovation Group introduced the third phase of the program:
engagement. Armed with the habit and the tools, employees were introduced to a new
framework through which they could apply their new learnings to their own business
group. Up to this point, the process of generating new ideas had been an individual
pursuit on subject matters that were at the individual’s discretion. Employees were now
given “focus topics” on which to concentrate their newly honed creative thinking skills.
These topics were framed in the positive, for example, “Generate new ideas in relation to
…”. Topics included new processes to improve customer service, work-life balance,
introducing meeting efficiencies, and maximising synergies between business units.
By the beginning of 2005, each employee was expected to come up with at least two
ideas per month in response to a new focus topic announced by the team leader. (Sales
staff, who were introduced to the de Bono tools in February, were required to come up
with one idea per month.) Individuals were still required to come up with their quota of
ideas, but a series of three-hour off-site group sessions held throughout the year
ensured that focus topics were also addressed on a team basis using Six Hats, Random
Word and Concept Triangle. Focus topics were related to business units.
As the program developed, and as employees became comfortable with the de Bono
tools, further training was conducted to provide employees with a deeper understanding
of the thinking tools, including a one-day “step-up” training session with de Bono Institute
trainers Mackie and Overall. Team leaders also attended a “creative behaviours”
workshop. Such reinforcement was considered critical to “embedding” the use of creative
thinking tools within the organisation.
By the end of August, the innovation program had generated a total of 2,500 ideas.
Epstein estimates 125 – or 5% – of those ideas were earmarked as contenders. But he
Rethink: The Story of Edward de Bono in Australia
“Ideas are never lost, they’re always valuable. It’s just that for some ideas, the time is not
right. A lot of it is timing, what’s not right six months ago is right now. It could be that they
are not strategically aligned with current priorities or they don’t reflect core competencies
of the time. There has to be a culling of ideas, I think everybody understands that, but
we reassure people that placing an idea on the backburner is not another way of saying
RIP to that idea. That’s why follow-through is key and backburner ideas are regularly
reviewed. At one point we reviewed 700 backburner ideas and we pulled out 30-35 ideas
for further consideration because of changes to the business landscape.”
Epstein says the principal objective of the program was to develop people’s innovative
thinking skills and to create a culture of thinking. The Innovation Group’s original
contention that the success of the program would rest on the three principles of action,
simplicity and follow-through has proven correct. Central to the program’s success,
according to Epstein, has been the use of de Bono thinking tools.
“Using the tools gets buy-in at all levels. Because of the tools’ simplicity, everyone, from
the receptionist onwards, can contribute to creating a new way of working across the
business. The tools make it possible to bring in thinking from any direction. People are
using tools, expressing ideas and thinking, and as they experiment with tools, they go
beyond the expected. It’s about fresher thinking. It’s about encouraging the freshness of
ideas. This is a function of the program, but it’s the tools that make it possible. People
develop a belief in their own creativity.”
Regular team sessions to consider focus topics as a group have also been a positive
feature of the program: “When you share ideas they build on each other. It’s also been
important to reinforce innovation as something everyone can do and everyone can share
Epstein says one of the benefits of the tools – Six Hats in particular – has been the
introduction of a “common language” in relation to creative thinking. “Someone will say,
‘let’s Green Hat this’, and everyone knows what they mean,” he says. Six Hats also
creates a new dynamic in meetings, with the focus being on everyone having an
opportunity to offer information and opinions in a non-critical environment. “Ensuring that
you don’t get dominant people in meetings – which is what happens in most meetings –
Rethink: The Story of Edward de Bono in Australia
has been so important to fostering a creative environment.” In case the message is lost
on participants, all meeting rooms feature posters of the Six Hats.
“People use the Six Hats language. It’s resonating, even with the sales force. A team
leader recently had to present her sales force with new objectives, and she received a
very negative response, so much so that she thought it would be counter-productive to
continue the meeting. She postponed the meeting to the next day, allowing tempers to
cool. She used the hats to conduct the meeting and there was a 360 degree turnaround
Perhaps the most visually striking illustration of the impact of the de Bono tools at Pfizer
Australia was the decision by the company to launch an Innovation Room at its Sydney
headquarters in late 2005. The ceiling is divided into the Six Hat colours. “It’s a physical
and symbolic representation of our commitment to innovation,” Epstein says.
2 Salvatore Giorgianni, ‘Protecting the Ecosystem for Medical and Pharmaceutical Research’(editorial), The Pfizer Journal, vol 3, no 2, Pfizer Inc, New York, Summer 1999.
3 As a pioneer in fermentation and mass-production technologies, Pfizer played a critical role inthe onset of the modern pharmaceutical era. Among Pfizer’s firsts were the mass production of
citrus acid in 1919 and Vitamin C in 1936 and, most significantly, the mass production of penicillin
in the 1940s. In 1950, Pfizer launched its first proprietary pharmaceutical product, Terramycin, a
broad-spectrum antibiotic, which simultaneously spearheaded the creation of Pfizer’s
pharmaceutical division and its international operations. Over the next 50 years and into the new
century, Pfizer’s portfolio of medicines would become one of the pharmaceutical industry’s most
formidable, although today the company is arguably best known for Viagra, its breakthrough
treatment for erectile dysfunction, launched in 1998 and developed at a cost of $US3.3 billion.
(These highlights were sourced from ‘Exploring Our History’ on Pfizer’s corporate website at
www.pfizer.com/pfizer/history, which in turn is based on The Legend of Pfizer by Jeffrey L.
Rodengen. 1999 by Write Stuff Syndicate, Inc.)
Rethink: The Story of Edward de Bono in Australia
Gebrauchsinformation: Information für den Anwender Myambutol® 400 mg, Filmtabletten Wirkstoff: Ethambutoldihydrochlorid Zur Anwendung bei Kindern ab 6 Jahren und Erwachsenen Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme dieses Arzneimittels beginnen. Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals lesen
Press Release May 5, 2010 It Gets Personal at The 3rd New Asia Film Festival Cutting-edge Films Explore the Inner Landscape of Contemporary Asian Culture Richmond, BC – May 4th, 2010 – Co-presented by the City of Richmond and Cinevolution Media Arts Society, New Asia Film Festival is the leading international film event in Richmond. Its third annual festival will be taking pl